Despite evidence reporting mitochondrial dysfunction in PSP, no studies have examined if mtDNA background influences PSP or CBD risk or if mtDNA variation can contribute to overall tau pathology severity. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.